Outcomes of Percutaneous Coronary Intervention Versus Optimal Medical Treatment for Chronic Total Occlusion: A

Insights

Percutaneous coronary intervention for chronic total occlusion (CTO-PCI) may reduce mortality compared to optimal medical therapy alone. However, these benefits were mainly observed in observational studies, not randomized controlled trials, necessitating further research.

Area of Science:

  • Cardiology
  • Interventional Cardiology

Background:

  • Concurrent chronic total occlusion (CTO) significantly predicts mortality.
  • Percutaneous coronary intervention (PCI) for CTO has shown clinical benefits.

Purpose of the Study:

  • To compare the outcomes of CTO-PCI versus optimal medical therapy (OMT) through a meta-analysis.
  • To evaluate the impact of CTO-PCI on mortality, cardiac events, and stroke.

Main Methods:

  • A meta-analysis of 16 studies (11,314 patients) published between 2006-2019.
  • Searched PubMed, ClinicalTrials.gov, Google Scholar, and Cochrane Central Register.
  • Analyzed mortality, cardiac deaths, myocardial re-infarction, MACE, stroke, and repeat PCI using random-effects models.

Main Results:

  • CTO-PCI was associated with significantly lower mortality (OR: 0.45) and cardiac deaths (OR: 0.58) compared to OMT alone.
  • These findings were primarily driven by observational studies; no significant differences were found in randomized controlled trials.
  • No significant differences were observed in major adverse cardiac events, myocardial re-infarction, stroke, or repeat PCI.

Conclusions:

  • CTO-PCI may reduce long-term mortality and cardiac deaths compared to OMT, but this is primarily based on observational data.
  • The benefits of CTO-PCI require confirmation from further randomized controlled trials.
  • More research is needed to fully evaluate the long-term outcomes of CTO-PCI versus OMT.

Related Concept Videos

Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
153
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
131
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
148
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
157
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
221
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
118